Physician profile
Michael L Bowen
NPI 1336299098
$2,048.95
in general payments reported to CMS, 2019-2025
19 companies · $475 in 2025
The $475 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $50.88 · 2021: $42.33 · 2022: $103 · 2023: $372 · 2024: $515 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $309.82 | 2023-2025 | Azstarys |
| Glaxosmithkline, LLC. | $223.18 | 2019-2022 | |
| Stryker Corporation | $171.72 | 2024 | Triathlon |
| Pfizer INC. | $160.45 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $150.14 | 2025 | |
| Gm Pharmaceuticals, INC. | $147.22 | 2023 | Vanacof |
| Astrazeneca Pharmaceuticals LP | $136.19 | 2024 | Fasenra, Flumist Quadrivalent |
| Tris Pharma INC | $135.61 | 2019 | |
| Lilly USA, LLC | $121.87 | 2023 | Mounjaro |
| Phathom Pharmaceuticals, INC. | $116.76 | 2024 | Voquezna |
| Abbvie INC. | $99.85 | 2019 | |
| Sanofi Pasteur INC. | $73.77 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $64.61 | 2024-2025 | Vaxelis, Gardasil, Gardasil 9 |
| Supernus Pharmaceuticals, INC. | $28.85 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.75 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $24.60 | 2025 | Inspire |
| Biogen, INC. | $24.21 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.77 | 2025 | Jornay Pm |
| Genentech USA, INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.